GLN Management for DSCSA Compliance: What Wholesale Distributors Need to Know

The Drug Supply Chain Security Act (DSCSA) requires wholesale distributors to exchange serialized product tracing data using EPCIS 1.2 format, and that data must include GS1 Global Location Numbers (GLNs) to identify all physical locations where product is received, stored, or shipped. As of November 27, 2024 — the Enhanced Drug Distribution Security (EDDS) enforcement date — FDA expects distributors to populate EPCIS messages with valid, registered GLNs for every facility in their network.

Regulatory Context

DSCSA's interoperable data exchange requirement, outlined in Section 582(g)(1) of the FD&C Act and codified in 21 CFR Part 582, mandates that trading partners use a standardized, electronic system to verify product history and authenticity. FDA adopted EPCIS 1.2 as the interoperability standard and GS1 identifiers (GTIN, SGTIN, GLN) as the data carriers.

GLNs serve as unique identifiers for physical locations within the pharmaceutical supply chain. Under DSCSA, every location that receives, stores, or ships prescription drug products must be assigned a distinct GLN. This includes:

• Distribution center warehouses
• Cross-dock facilities
• Third-party logistics (3PL) sites operated under contract
• Return centers processing saleable returns

FDA guidance (published December 2022 in "Product Identifier Requirements Under the Drug Supply Chain Security Act — Questions and Answers") clarifies that GLNs must be GS1-issued, registered in the GS1 Global Registry, and maintained as active. Self-assigned or internally generated location codes do not satisfy DSCSA requirements.

GLN Registration and Maintenance Requirements

Wholesale distributors must obtain GLNs through a GS1 Member Organization (in the U.S., GS1 US). The registration process requires:

1. GS1 Company Prefix — A globally unique prefix assigned to the company. This prefix forms the root of all GLNs the company generates.
2. Location-specific allocation — Each physical location receives a unique GLN derived from the company prefix. A single company with 15 warehouses must register 15 distinct GLNs.
3. Global Registry publication — All GLNs must be published to the GS1 Global Registry (formerly GEPIR) so trading partners can validate them during EPCIS message exchange.
4. Annual renewal — GS1 Company Prefixes and associated GLNs require annual renewal. Lapsed GLNs become invalid and will fail Verification Router Service (VRS) checks.

For 3PLs operating facilities on behalf of multiple wholesale distributor clients, GLN ownership rests with the legal entity that holds the wholesale drug distributor license for that location. If the 3PL holds the license, the 3PL assigns the GLN. If the distributor holds the license and the 3PL is operating under contract, the distributor assigns the GLN. FDA expects each license-holding entity to maintain accurate GLN records for every location listed on state pharmacy board licenses.

Impact on EPCIS Data Exchange

DSCSA EPCIS messages include GLNs in multiple fields:

• Source GLN — The location where product was shipped from
• Destination GLN — The location where product will be received
• Current Location GLN — The location generating the EPCIS event (for commissioning, aggregation, or observation events)

Trading partners receiving EPCIS data will cross-reference GLNs against the GS1 Global Registry to confirm the location is valid and associated with a licensed entity. VRS queries may also incorporate GLN validation as part of ATP (Authorized Trading Partner) verification workflows. A mismatch — such as a shipment claiming to originate from a GLN not registered to the sender — flags a potential data integrity issue and may trigger an investigation under DSCSA's suspect product provisions (21 CFR 582.23).

For wholesale distributors managing multi-site operations, GLN governance becomes a compliance control. If a distributor acquires a new warehouse, the GLN must be registered before that facility can generate EPCIS shipment events. If a facility closes, the associated GLN should be retired from the Global Registry to prevent its reuse in fraudulent transactions.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these, 1,234 hold active FDA registration — a baseline requirement for DSCSA compliance. However, FDA registration alone does not confirm GLN registration or EPCIS readiness. The average compliance score across the directory is 51/100, placing the majority of entities (919) in the "Fair" tier. This score reflects verified licensure, accreditation, and enforcement history, but does not yet incorporate GLN validation — a data point ColdChainCheck is evaluating for future enrichment.

The compliance score distribution suggests uneven preparedness for enhanced DSCSA requirements:

• 28 entities (Excellent tier, 70-100 pts) — These distributors typically hold NABP accreditation (63 total in the directory), maintain active licenses in multiple jurisdictions, and have clean enforcement records. They are more likely to have invested in EPCIS infrastructure and GLN governance.
• 281 entities (Good tier, 50-69 pts) — Mid-tier distributors with strong state licensure coverage but fewer third-party validations. GLN registration status varies widely in this group.
• 919 entities (Fair tier, 30-49 pts) — The largest segment. Many are single-state or regional operators with minimal cross-referenced compliance signals. GLN governance may not be prioritized until enforcement actions begin.
• 47 entities (Poor/Minimal tiers, <30 pts) — Limited verifiable data. These entities may lack FDA registration, hold only a single state license, or have lapsed credentials.

Practical Guidance for Compliance Teams

If you are qualifying a new wholesale distributor:

• Cross-reference FDA registration and state licensure using the ColdChainCheck directory. Filter by state and verify the entity holds active licenses in jurisdictions where they claim to operate facilities.
• Request GLN documentation — Ask the distributor to provide their GS1 Company Prefix and a list of GLNs for all licensed locations. Verify these GLNs appear in the GS1 Global Registry (search at gepir.gs1.org).
• Confirm 3PL GLN ownership — If the distributor uses third-party warehousing, clarify which entity holds the wholesale drug distributor license for each facility. The license holder must control the GLN.
• Check enforcement history — ColdChainCheck tracks 73 entities with FDA recalls on record. A history of data integrity issues or labeling violations may indicate weak EPCIS controls.

If you manage an existing distributor network:

• Audit your trading partners' GLN status annually — Lapsed GS1 Company Prefixes invalidate all associated GLNs. Build GLN expiration checks into your ATP monitoring workflow.
• Monitor for facility changes — New warehouse locations require new GLNs. Use ColdChainCheck's state license data to flag when a distributor adds or closes facilities (reflected in license amendments).

ColdChainCheck continues to expand coverage of DSCSA-related compliance signals. For broader context on wholesale distributor qualification, see the Compliance Guides section.

Disclaimer: This article provides informational content based on publicly available regulatory guidance and ColdChainCheck directory data. It is not legal advice. Consult with qualified regulatory counsel and verify all compliance requirements with the relevant authorities.